<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204889</url>
  </required_header>
  <id_info>
    <org_study_id>TOALS</org_study_id>
    <secondary_id>8009</secondary_id>
    <nct_id>NCT04204889</nct_id>
  </id_info>
  <brief_title>Trial of Oxaloacetate in ALS</brief_title>
  <acronym>TOALS</acronym>
  <official_title>Trial of Oxaloacetate in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omar Jawdat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research in ALS and Related Disorders for Therapeutic Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terra Biological LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and the maximal tolerated dose of&#xD;
      Oxaloacetate (OAA) in patients with Amyotrophic Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview This is a safety and dose finding study looking at Oxaloacetate (OAA) in patients&#xD;
      with Amyotrophic Lateral Sclerosis (ALS). This study will aim to determine the maximal dose&#xD;
      that a person can tolerate. We will also learn how OAA affects mitochondria in subjects with&#xD;
      ALS. This is a 28 day study in which we will attempt to enroll approximately 24 participants.&#xD;
      Participants will know that they are on OAA.&#xD;
&#xD;
      Specific Aims (Hypothesis and Objectives)&#xD;
&#xD;
      The overall goal of this proposal is to determine if reducing mitochondrial stress is a&#xD;
      viable treatment strategy for ALS. This study will determine the maximal tolerated dose of&#xD;
      OAA and whether OAA improves biomarkers of mitochondrial stress. ALS is a progressive fatal&#xD;
      neurodegenerative disorder caused by loss of motor neurons in the brain and spinal cord.&#xD;
      Despite multiple clinical trials and advances in understanding of the pathogenesis of ALS,&#xD;
      riluzole and edaravone, the only Food and Drug Administration (FDA) approved ALS drugs, the&#xD;
      former only extends life by a few months, and the latter possibly slows down functional&#xD;
      decline. Hence there is a clear need for new treatments for ALS.&#xD;
&#xD;
      While the exact underlying cause of this motor neuron degeneration remains uncertain,&#xD;
      candidate mechanisms include glutamate excitotoxicity, free radical-mediated oxidative&#xD;
      cytotoxicity, neuroinflammation, mitochondrial dysfunction, autoimmune processes, protein&#xD;
      aggregation, and cytoskeletal abnormalities. Mitochondrial dysfunction in particular may play&#xD;
      a critical role in ALS neurodegeneration, an observation supported by both human and animal&#xD;
      model studies. The characteristic pathological ALS finding of cytoplasmic inclusions (Bunina&#xD;
      bodies) in motor neuron cell bodies may represent mitochondria-containing autophagic&#xD;
      vacuoles. Functional studies of ALS mitochondria were also reported: calcium levels in motor&#xD;
      neuron synaptic terminals of ALS subjects were found to be elevated despite increased numbers&#xD;
      of local mitochondria, suggesting a defect of mitochondrial calcium sequestration; increased&#xD;
      complex I activity was seen with familial ALS; and reduced cytochrome oxidase activity was&#xD;
      shown in sporadic ALS patients. In mutant SOD mouse model, evidence of mitochondrial&#xD;
      dysfunction appears before motor neuron degeneration. Similar observations have been noted in&#xD;
      human sporadic ALS tissue. In humans with pathogenic mutations in TARDBP and C9ORF72,&#xD;
      mitochondrial functionality is abnormal in peripheral fibroblasts. The dexpramipexole trial&#xD;
      in ALS, while negative, is based on the mitochondrial ALS pathogenesis theory. We performed&#xD;
      an open label study of rasagiline in ALS and demonstrated target engagement of several blood&#xD;
      mitochondrial biomarkers. We completed an 80 patient randomized controlled trial of&#xD;
      rasagiline in ALS and again we measured mitochondrial biomarkers.&#xD;
&#xD;
      Rationale: Human and animal studies suggest targeting mitochondrial dysfunction may be an&#xD;
      important approach to slow disease progression in ALS. Mitochondrial dysfunction can be seen&#xD;
      in both in vitro and in vivo experimental ALS models, may explain the characteristic Bunina&#xD;
      bodies, a key ALS pathological hallmark, and mitochondrial abnormalities are found in patient&#xD;
      autopsies. In cell models of mitochondrial dysfunction, OAA has been shown to be&#xD;
      cytoprotective. In addition, there is evidence that OAA, in preclinical studies in Alzheimer&#xD;
      disease, reduces neuroinflammation, another possible ALS pathological pathway. A phase 2&#xD;
      trial of OAA in in Alzheimer Disease is currently being conducted at KUMC but at a lower dose&#xD;
      than is proposed in this ALS study. We are interested in OAA as a potential therapeutic agent&#xD;
      in ALS as it crosses the blood brain barrier, accesses motor neurons, activates mitochondrial&#xD;
      bioenergetics, increases respiratory capacity, and increases glycolysis capacity. Preliminary&#xD;
      data of OAA in an ALS mouse model at KUMC increased muscle strength compared to untreated&#xD;
      animals.&#xD;
&#xD;
      Hypothesis: OAA will be neuroprotective in ALS by reducing mitochondrial stress. This trial&#xD;
      will determine whether OAA is tolerable and whether it engages mitochondrial targets in ALS&#xD;
      patients. The result of this trial will lead to a larger phase II trial to further assess&#xD;
      safety and to begin to study efficacy in slowing the disease process. This short 28 day study&#xD;
      is too brief to study efficacy.&#xD;
&#xD;
      Specific Aim 1: To determine safety and the maximal tolerated dose of OAA in patients with&#xD;
      ALS. To achieve this aim we will conduct a prospective 3 + 3 dose escalating clinical trial&#xD;
      in up to 24 clinically definite, probable, or laboratory supported probable ALS patients.&#xD;
&#xD;
      Sub-aim 1: We will determine the pharmacokinetic profile of OAA in ALS patients. We will&#xD;
      evaluate OAA drug levels in a pre-dose sample, 1 hour and 4 hours after dosing.&#xD;
&#xD;
      Specific Aim 2: To determine OAA target engagement. We will evaluate a panel of mitochondrial&#xD;
      biomarkers, platelet TDP-43 levels and MR spectroscopy of brain glutathione, at baseline then&#xD;
      at the end of treatment and compare biomarker levels to dose, to evaluate possible&#xD;
      dose-response relationship in our biomarkers.&#xD;
&#xD;
      Future Aim: Our goal is to use the results from this study to conduct a larger prospective&#xD;
      placebo controlled trial to determine if OAA is well tolerated and slows disease progression&#xD;
      in ALS using the maximal tolerated dose that will be determined during this current study&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLT)</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as any serious adverse event related to OAA requiring hospitalization, or any AE related to OAA requiring stopping the medication, inculding a two fold increase in AST and/or LAT and /or a 1.5 times increase in creatinine level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic testing</measure>
    <time_frame>Day 28</time_frame>
    <description>OAA Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Biomarkers</measure>
    <time_frame>Day 28</time_frame>
    <description>Annexin V/Mitotracker in lymphocytes: assess modification of apoptosis/mitochondrial number. TMRE: Mitochondrial membrane potential. MitoSox: Mitochondrial superoxide. Glutamate-plasma: OAA specific biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Biomarker</measure>
    <time_frame>Day 28</time_frame>
    <description>The levels of Serum TDP43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR spectroscopy</measure>
    <time_frame>Day 28</time_frame>
    <description>MR spectroscopy of brain glutathione</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Oxaloacetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaloacetic Acid</intervention_name>
    <description>The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.</description>
    <arm_group_label>Oxaloacetate</arm_group_label>
    <other_name>Oxaloacetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis by a study investigator of laboratory-supported probable,&#xD;
             probable, or definite ALS, according to the modified El Escorial criteria[1]&#xD;
&#xD;
          -  Vital capacity (VC) greater or equal to 50% of predicted&#xD;
&#xD;
          -  Diagnosis with ALS within 3 years prior to enrollment&#xD;
&#xD;
          -  If patients are taking riluzole for ALS, they must be on a stable dose for at least&#xD;
             thirty days prior to the baseline visit&#xD;
&#xD;
          -  Women of childbearing age must use protection against pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement for tracheotomy ventilation or non-invasive ventilation for &gt; 23 hours per&#xD;
             day&#xD;
&#xD;
          -  Diagnosis of other neurodegenerative diseases (e.g., Parkinson disease, Alzheimer&#xD;
             disease)&#xD;
&#xD;
          -  Clinically significant history of unstable medical illness (e.g., unstable angina,&#xD;
             advanced cancer) over the last 30 days&#xD;
&#xD;
          -  Current pregnancy or lactation&#xD;
&#xD;
          -  Limited mental capacity such that the patient cannot provide written informed consent&#xD;
             or comply with evaluation procedures&#xD;
&#xD;
          -  Receipt of any investigational drug within the past 30 days from enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Jawdat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Herbelin</last_name>
    <phone>913-588-5095</phone>
    <email>lherbelin@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Collin Gerringer</last_name>
    <phone>913-574-0008</phone>
    <email>cgerringer@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Omar Jawdat</investigator_full_name>
    <investigator_title>Omar Jawdat MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

